Keybank National Association OH lowered its holdings in Allergan plc (NYSE:AGN) by 41.6% during the 3rd quarter, HoldingsChannel.com reports. The fund owned 1,456 shares of the company’s stock after selling 1,037 shares during the quarter. Keybank National Association OH’s holdings in Allergan were worth $245,000 at the end of the most recent reporting period.
Several other large investors have also added to or reduced their stakes in AGN. Haverford Trust Co. raised its holdings in shares of Allergan by 14.6% during the 2nd quarter. Haverford Trust Co. now owns 4,438 shares of the company’s stock valued at $743,000 after buying an additional 565 shares in the last quarter. Alps Advisors Inc. increased its stake in Allergan by 4.4% in the 2nd quarter. Alps Advisors Inc. now owns 6,938 shares of the company’s stock worth $1,162,000 after purchasing an additional 292 shares during the period. Fulton Bank N.A. increased its stake in Allergan by 19.9% in the 2nd quarter. Fulton Bank N.A. now owns 14,220 shares of the company’s stock worth $2,381,000 after purchasing an additional 2,360 shares during the period. Rational Advisors LLC increased its stake in Allergan by 650.0% in the 2nd quarter. Rational Advisors LLC now owns 285 shares of the company’s stock worth $48,000 after purchasing an additional 247 shares during the period. Finally, Fjarde AP Fonden Fourth Swedish National Pension Fund increased its stake in Allergan by 1.0% in the 3rd quarter. Fjarde AP Fonden Fourth Swedish National Pension Fund now owns 93,208 shares of the company’s stock worth $15,686,000 after purchasing an additional 900 shares during the period. 80.64% of the stock is currently owned by hedge funds and other institutional investors.
A number of equities analysts have commented on the company. ValuEngine cut Allergan from a “hold” rating to a “sell” rating in a research note on Wednesday, October 30th. Barclays lifted their price target on Allergan from $176.00 to $188.00 and gave the stock an “equal weight” rating in a research note on Wednesday, August 7th. Guggenheim cut Allergan from a “buy” rating to a “neutral” rating in a research note on Wednesday, August 7th. Wells Fargo & Co reaffirmed an “outperform” rating and issued a $184.00 price target (up from $176.00) on shares of Allergan in a research note on Monday, September 30th. Finally, Cantor Fitzgerald lifted their price target on Allergan from $125.00 to $165.00 and gave the stock a “neutral” rating in a research note on Wednesday, August 7th. Two investment analysts have rated the stock with a sell rating, fifteen have given a hold rating and five have issued a buy rating to the company’s stock. Allergan presently has a consensus rating of “Hold” and an average price target of $175.16.
Shares of AGN stock opened at $183.61 on Friday. The firm has a market cap of $59.62 billion, a P/E ratio of 11.00, a P/E/G ratio of 2.14 and a beta of 1.66. Allergan plc has a fifty-two week low of $114.27 and a fifty-two week high of $183.79. The business’s 50 day moving average price is $173.45 and its 200-day moving average price is $156.92. The company has a debt-to-equity ratio of 0.33, a quick ratio of 0.88 and a current ratio of 1.00.
Allergan (NYSE:AGN) last issued its quarterly earnings data on Tuesday, November 5th. The company reported $4.25 earnings per share for the quarter, hitting the Zacks’ consensus estimate of $4.25. The firm had revenue of $4.03 billion for the quarter, compared to analyst estimates of $3.88 billion. Allergan had a positive return on equity of 9.08% and a negative net margin of 58.50%. The business’s quarterly revenue was up 2.9% compared to the same quarter last year. During the same period last year, the company earned $4.25 EPS. As a group, equities analysts predict that Allergan plc will post 16.87 EPS for the current year.
The firm also recently disclosed a quarterly dividend, which will be paid on Friday, December 13th. Stockholders of record on Wednesday, November 13th will be given a $0.74 dividend. The ex-dividend date is Tuesday, November 12th. This represents a $2.96 dividend on an annualized basis and a dividend yield of 1.61%. Allergan’s dividend payout ratio is currently 17.74%.
Allergan plc, a pharmaceutical company, develops, manufactures, and commercializes branded pharmaceutical, device, biologic, surgical, and regenerative medicine products worldwide. The company operates in three segments: US Specialized Therapeutics, US General Medicine, and International. It offers a portfolio of products in various therapeutic areas, including medical aesthetics and dermatology, eye care, neuroscience, urology, gastrointestinal, women's health, and anti-infective therapeutic products.
Featured Story: What is a capital gain?
Want to see what other hedge funds are holding AGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Allergan plc (NYSE:AGN).
Receive News & Ratings for Allergan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan and related companies with MarketBeat.com's FREE daily email newsletter.